How I monitor residual disease in chronic myeloid leukemia

被引：38

作者：

Radich, Jerald P. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA

来源：

BLOOD | 2009年 / 114卷 / 16期

关键词：

KINASE DOMAIN MUTATIONS; HARMONIZING CURRENT METHODOLOGY; COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; POLYMERASE-CHAIN-REACTION; ALPHA PLUS CYTARABINE; BCR-ABL TRANSCRIPTS; CHRONIC-PHASE; MARROW-TRANSPLANTATION; MOLECULAR RESPONSES;

D O I：

10.1182/blood-2009-02-163485

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and "guidelines" using the molecular endpoints of CML has out-paced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic. (Blood. 2009;114:3376-3381)

引用

页码：3376 / 3381

页数：6

共 33 条

[1] A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS [J].

Baccarani, M. ;

Haznedaroglu, I. ;

Porkka, K. ;

Castagnetti, F. ;

Alberti, D. ;

Alimena, G. ;

Amabile, M. ;

Bostrom, H. ;

Hjorth-Hansen, H. ;

Kairisto, V. ;

Martinelli, G. ;

Nielsen, J. ;

Palandri, F. ;

Pane, F. ;

Rege-Cambrin, G. ;

Russo, D. ;

Saglio, G. ;

Specchia, G. ;

Testoni, N. ;

Weiss-Bjerrum, O. ;

Rosti, G. ;

Simonsson, B. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :161-162

[2] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[3] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia [J].

Branford, S. ;

Cross, N. C. P. ;

Hochhaus, A. ;

Radich, J. ;

Saglio, G. ;

Kaeda, J. ;

Goldman, J. ;

Hughes, T. .

LEUKEMIA, 2006, 20 (11) :1925-1930

[4] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[5] Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].

Branford, S ;

Rudzki, Z ;

Harper, A ;

Grigg, A ;

Taylor, K ;

Durrant, S ;

Arthur, C ;

Browett, P ;

Schwarer, AP ;

Ma, D ;

Seymour, JF ;

Bradstock, K ;

Joske, D ;

Lynch, K ;

Gathmann, I ;

Hughes, TP .

LEUKEMIA, 2003, 17 (12) :2401-2409

[6] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].

Branford, Susan ;

Fletcher, Linda ;

Cross, Nicholas C. P. ;

Mueller, Martin C. ;

Hochhaus, Andreas ;

Kim, Dong-Wook ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Kamel-Reid, Suzanne ;

Wang, Y. Lynn ;

Press, Richard D. ;

Lynch, Kevin ;

Rudzki, Zbigniew ;

Goldman, John M. ;

Hughes, Timothy .

BLOOD, 2008, 112 (08) :3330-3338

[7] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate [J].

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Jones, D ;

Luthra, R ;

Shan, J ;

Giles, F ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Rios, MB ;

Kantarjian, H .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3425-3432

[8]

Druker BJ, 2006, J CLIN ONCOL, V24, p338S

[9] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[10] Periodic chronic myelogenous leukaemia: spectral analysis of blood cell counts and aetiological implications [J].

Fortin, P ;

Mackey, MC .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) :336-345

← 1 2 3 4 →